Doxorubicin-induced cardiovascular toxicity: a longitudinal evaluation of functional and molecular markers.
Matthias BosmanDustin KrügerCharles Van AsscheHanne BoenCédric NeutelKasper FavereConstantijn FranssenWim MartinetLynn RothGuido De MeyerBerta Cillero-PastorLeen DelrueWard HeggermontEmeline Van CraenenbroeckPieter-Jan GunsPublished in: Cardiovascular research (2023)
DOX increased arterial stiffness and impaired endothelial function, which both preceded reduced LVEF. Vascular dysfunction restored after DOX therapy cessation whereas cardiac dysfunction persisted. Further, we identified SERPINA3 and THBS1 as promising biomarkers of DOX-induced cardiovascular toxicity, which were confirmed in AICT patients.